Rola autoimmunizacji w rozwoju powikłań cukrzycowych – przegląd badań

[1]Ehrlich P.: On immunity with special reference to cell life. Proc. R. Soc. Lond., 1900; 66: 424-448Ehrlich P. On immunity with special reference to cell life Proc. R. Soc. Lond 1900 66 424 44810.1098/rspl.1899.0121Search in Google Scholar

[2]Steinman L.: Escape from “horror autotoxicus”: Pathogenesis and treatment of autoimmune disease. Cell, 1995; 80: 7-10Steinman L. Escape from “horror autotoxicus”: Pathogenesis and treatment of autoimmune disease Cell 1995 80 7 1010.1016/0092-8674(95)90443-3Search in Google Scholar

[3]Dighiero G., Lymberi P., Guilbert B., Ternynck T., Avrameas S.: Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins. Ann. N. Y. Acad. Sci., 1986; 475: 135145Dighiero G. Lymberi P. Guilbert B. Ternynck T. Avrameas S. Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins Ann. N. Y. Acad. Sci 1986 475 13514510.1111/j.1749-6632.1986.tb20863.xSearch in Google Scholar

[4]Bottazzo G.F., Florin-Christensen A., Doniach D.: Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet, 1974; 2: 1279-1283Bottazzo G.F. Florin-Christensen A. Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies Lancet 1974 2 1279 128310.1016/S0140-6736(74)90140-8Search in Google Scholar

[5]Wilkin T.J.: The accelerator hypothesis: Weight gain as the missing link between type I and type II diabetes. Diabetologia, 2001; 44: 914-922Wilkin T.J. The accelerator hypothesis: Weight gain as the missing link between type I and type II diabetes Diabetologia 2001 44 914 92210.1007/s00125010054811508279Search in Google Scholar

[6]Wilkin T.J.: The accelerator hypothesis: A review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int. J. Obes., 2009; 33: 716-726Wilkin T.J. The accelerator hypothesis: A review of the evidence for insulin resistance as the basis for type I as well as type II diabetes Int. J. Obes 2009 33 716 72610.1038/ijo.2009.9719506563Search in Google Scholar

[7]Zhou T., Hu Z., Yang S., Sun L., Yu Z., Wang G.: Role of adaptive and innate immunity in type 2 diabetes mellitus. J. Diabetes Res., 2018; 2018: 7457269Zhou T. Hu Z. Yang S. Sun L. Yu Z. Wang G. Role of adaptive and innate immunity in type 2 diabetes mellitus J. Diabetes Res 2018 2018 745726910.1155/2018/7457269625001730533447Search in Google Scholar

[8]Moura J., Madureira P., Leal E.C., Fonseca A.C., Carvalho E.: Immune aging in diabetes and its implications in wound healing. Clin. Immunol., 2019; 200: 43-54Moura J. Madureira P. Leal E.C. Fonseca A.C. Carvalho E. Immune aging in diabetes and its implications in wound healing Clin. Immunol 2019 200 43 5410.1016/j.clim.2019.02.002732293230735729Search in Google Scholar

[9]Winer D.A., Winer S., Shen L., Wadia P.P., Yantha J., Paltser G., Tsui H., Wu P., Davidson M.G., Alonso M.N. i wsp.: B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med., 2011; 17: 610-617Winer D.A. Winer S. Shen L. Wadia P.P. Yantha J. Paltser G. Tsui H. Wu P. Davidson M.G. Alonso M.N. i wsp. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies Nat. Med 2011 17 610 61710.1038/nm.2353327088521499269Search in Google Scholar

[10]Winer S., Chan Y., Paltser G., Truong D., Tsui H., Bahrami J., Dorfman R., Wang Y., Zielenski J., Mastronardi F. i wsp.: Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med., 2009; 15: 921-929Winer S. Chan Y. Paltser G. Truong D. Tsui H. Bahrami J. Dorfman R. Wang Y. Zielenski J. Mastronardi F. i wsp. Normalization of obesity-associated insulin resistance through immunotherapy Nat. Med 2009 15 921 92910.1038/nm.2001306319919633657Search in Google Scholar

[11]Cooper G.S., Bynum M.L., Somers E.C.: Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J. Autoimmun., 2009; 33: 197-207Cooper G.S. Bynum M.L. Somers E.C. Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases J. Autoimmun 2009 33 197 20710.1016/j.jaut.2009.09.008278342219819109Search in Google Scholar

[12]Gianchecchi E., Fierabracci A.: Recent advances on microbiota involvement in the pathogenesis of autoimmunity. Int. J. Mol. Sci., 2019; 20: 283Gianchecchi E. Fierabracci A. Recent advances on microbiota involvement in the pathogenesis of autoimmunity Int. J. Mol. Sci 2019 20 28310.3390/ijms20020283635951030642013Search in Google Scholar

[13]Hewagama A., Richardson B.: The genetics and epigenetics of autoimmune diseases. J. Autoimmun., 2009; 33: 3-11Hewagama A. Richardson B. The genetics and epigenetics of autoimmune diseases J. Autoimmun 2009 33 3 1110.1016/j.jaut.2009.03.007281941819349147Search in Google Scholar

[14]Romagnani S.: Immunological tolerance and autoimmunity. Intern. Emerg. Med., 2006; 1: 187-196Romagnani S. Immunological tolerance and autoimmunity Intern. Emerg. Med 2006 1 187 19610.1007/BF0293473617120464Search in Google Scholar

[15]Tomer Y.: Mechanisms of autoimmune thyroid diseases: From genetics to epigenetics. Annu. Rev. Pathol., 2014; 9: 147-156Tomer Y. Mechanisms of autoimmune thyroid diseases: From genetics to epigenetics Annu. Rev. Pathol 2014 9 147 15610.1146/annurev-pathol-012513-104713412863724460189Search in Google Scholar

[16]Jacobson E.M., Huber A,. Tomer Y.: The HLA gene complex in thyroid autoimmunity: From epidemiology to etiology. J. Autoimmun., 2008; 30: 58-62 Jacobson E.M. Huber A Tomer Y. The HLA gene complex in thyroid autoimmunity: From epidemiology to etiology J. Autoimmun 2008 30 58 6210.1016/j.jaut.2007.11.010224491118178059Search in Google Scholar

[17]Burek C.L., Talor M.V.: Environmental triggers of autoimmune thyroiditis. J. Autoimmun., 2009; 33: 183-189Burek C.L. Talor M.V. Environmental triggers of autoimmune thyroiditis J. Autoimmun 2009 33 183 18910.1016/j.jaut.2009.09.001279018819818584Search in Google Scholar

[18]Yoshitake T., Murakami T., Yoshitake S., Suzuma K., Dodo Y., Fujimoto M., Ito S., Tsujikawa A.: Anti-hexokinase 1 antibody as a novel serum biomarker of a subgroup of diabetic macular edema. Sci. Rep., 2019; 9: 4806Yoshitake T. Murakami T. Yoshitake S. Suzuma K. Dodo Y. Fujimoto M. Ito S. Tsujikawa A. Anti-hexokinase 1 antibody as a novel serum biomarker of a subgroup of diabetic macular edema Sci. Rep 2019 9 480610.1038/s41598-019-39777-z642302730886155Search in Google Scholar

[19]Schroner Z., Lazurova I., Petrovicova J.: Autoimmune thyroid diseases in patients with diabetes mellitus. Bratisl. Lek. Listy, 2008; 109: 125-129Schroner Z. Lazurova I. Petrovicova J. Autoimmune thyroid diseases in patients with diabetes mellitus Bratisl. Lek. Listy 2008 109 125 129Search in Google Scholar

[20]Cerna M.: Epigenetic regulation in etiology of type 1 diabetes mellitus. Int. J. Mol. Sci., 2019; 21: 36Cerna M. Epigenetic regulation in etiology of type 1 diabetes mellitus Int. J. Mol. Sci 2019 21 3610.3390/ijms21010036698165831861649Search in Google Scholar

[21]Phillips B.E., Garciafigueroa Y., Engman C., Trucco M., Giannoukakis N.: Tolerogenic dendritic cells and T-regulatory cells at the clinical trials crossroad for the treatment of autoimmune disease; emphasis on type 1 diabetes therapy. Front. Immunol., 2019; 10: 148Phillips B.E. Garciafigueroa Y. Engman C. Trucco M. Giannoukakis N. Tolerogenic dendritic cells and T-regulatory cells at the clinical trials crossroad for the treatment of autoimmune disease; emphasis on type 1 diabetes therapy Front. Immunol 2019 10 14810.3389/fimmu.2019.00148637250530787930Search in Google Scholar

[22]Erichsen M.M., Løvås K., Skinningsrud B., Wolff A.B., Undlien D.E., Svartberg J., Fougner K.J., Berg T.J., Bollerslev J., Mella B. i wsp.: Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: Observations from a Norwegian registry. J. Clin. Endocrinol. Metab., 2009; 94: 4882-4890Erichsen M.M. Løvås K. Skinningsrud B. Wolff A.B. Undlien D.E. Svartberg J. Fougner K.J. Berg T.J. Bollerslev J. Mella B. i wsp. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: Observations from a Norwegian registry J. Clin. Endocrinol. Metab 2009 94 4882 489010.1210/jc.2009-136819858318Search in Google Scholar

[23]Bronstad I., Wolff A.S., Løvås K., Knappskog P.M., Husebye E.S.: Genome-wide copy number variation (CNV) in patients with autoimmune Addison’s disease. BMC Med. Genet., 2011; 12: 111Bronstad I. Wolff A.S. Løvås K. Knappskog P.M. Husebye E.S. Genome-wide copy number variation (CNV) in patients with autoimmune Addison’s disease BMC Med. Genet 2011 12 11110.1186/1471-2350-12-111316691121851588Search in Google Scholar

[24]Bjanesoy T.E., Andreassen B.K., Bratland E., Reiner A., Islam S., Husebye E.S., Bakke M.: Altered DNA methylation profile in Norwegian patients with autoimmune Addison’s disease. Mol. Immunol., 2014; 59: 208-216Bjanesoy T.E. Andreassen B.K. Bratland E. Reiner A. Islam S. Husebye E.S. Bakke M. Altered DNA methylation profile in Norwegian patients with autoimmune Addison’s disease Mol. Immunol 2014 59 208 21610.1016/j.molimm.2014.02.01824667071Search in Google Scholar

[25]Hellesen A., Bratland E.: The potential role for infections in the pathogenesis of autoimmune Addison’s disease. Clin. Exp. Immunol., 2019; 195: 52-63Hellesen A. Bratland E. The potential role for infections in the pathogenesis of autoimmune Addison’s disease Clin. Exp. Immunol 2019 195 52 6310.1111/cei.13207630064930144040Search in Google Scholar

[26]Hellesen A., Edvardsen K., Breivik L., Husebye E.S., Bratland E.: The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison’s disease. Clin. Exp. Immunol., 2017; 176: 351-362Hellesen A. Edvardsen K. Breivik L. Husebye E.S. Bratland E. The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison’s disease Clin. Exp. Immunol 2017 176 351 36210.1111/cei.12291400897924666275Search in Google Scholar

[27]Bizzaro N., Antico A.: Diagnosis and classification of pernicious anemia. Autoimmun. Rev., 2014; 13: 565-568Bizzaro N. Antico A. Diagnosis and classification of pernicious anemia Autoimmun. Rev 2014 13 565 56810.1016/j.autrev.2014.01.04224424200Search in Google Scholar

[28]Lahner E., Gentile G., Purchiaroni F., Mora B., Simmaco M., Annibale B.: Single nucleotide polymorphisms related to vitamin B12 serum levels in autoimmune gastritis patients with or without pernicious anaemia. Dig. Liver Dis., 2015; 47: 285-290Lahner E. Gentile G. Purchiaroni F. Mora B. Simmaco M. Annibale B. Single nucleotide polymorphisms related to vitamin B12 serum levels in autoimmune gastritis patients with or without pernicious anaemia Dig. Liver Dis 2015 47 285 29010.1016/j.dld.2015.01.14725681243Search in Google Scholar

[29]Lahner E., Annibale B.: Pernicious anemia: New insights from a gastroenterological point of view. World J. Gastroenterol., 2009; 15: 5121-5128Lahner E. Annibale B. Pernicious anemia: New insights from a gastroenterological point of view World J. Gastroenterol 2009 15 5121 512810.3748/wjg.15.5121277389019891010Search in Google Scholar

[30]Chou R., Bougatsos C., Blazina I., Mackey K., Grusing S., Selph S.: Screening for celiac disease: Evidence report and systematic review for the US preventive services task force. JAMA, 2017; 317: 1258-1268Chou R. Bougatsos C. Blazina I. Mackey K. Grusing S. Selph S. Screening for celiac disease: Evidence report and systematic review for the US preventive services task force JAMA 2017 317 1258 126810.1001/jama.2016.1039528350935Search in Google Scholar

[31]Ludvigsson J.F., Bai J.C., Biagi F., Card T.R., Ciacci C., Ciclitira P.J., Green P.H., Hadjivassiliou M., Holdoway A., van Heel D.A. i wsp.: D. Diagnosis and management of adult coeliac disease: Guidelines from the British Society of Gastroenterology. Gut, 2014; 63: 1210-1228Ludvigsson J.F. Bai J.C. Biagi F. Card T.R. Ciacci C. Ciclitira P.J. Green P.H. Hadjivassiliou M. Holdoway A. van Heel D.A. i wsp. D Diagnosis and management of adult coeliac disease: Guidelines from the British Society of Gastroenterology. Gut 2014 63 1210 122810.1136/gutjnl-2013-306578Search in Google Scholar

[32]Garner C.P., Murray J.A., Ding Y.C., Tien Z., van Heel D.A., Neuhausen S.L.: Replication of celiac disease UK genome-wide association study results in a US population. Hum. Mol. Genet., 2009; 18: 4219-4225Garner C.P. Murray J.A. Ding Y.C. Tien Z. van Heel D.A. Neuhausen S.L. Replication of celiac disease UK genome-wide association study results in a US population Hum. Mol. Genet 2009 18 4219 422510.1093/hmg/ddp364275814519648293Search in Google Scholar

[33]Ohlsson B., Ekblad E., Veress B., Montgomery A., Janciauskiene S.: Antibodies against gonadotropin-releasing hormone (GnRH) and destruction of enteric neurons in 3 patients suffering from gastrointestinal dysfunction. BMC Gastroenterol., 2010; 10: 48Ohlsson B. Ekblad E. Veress B. Montgomery A. Janciauskiene S. Antibodies against gonadotropin-releasing hormone (GnRH) and destruction of enteric neurons in 3 patients suffering from gastrointestinal dysfunction BMC Gastroenterol 2010 10 4810.1186/1471-230X-10-48288530720487533Search in Google Scholar

[34]Betterle C., Dal Pra C., Mantero F., Zanchetta R.: Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr. Rev., 2002; 23: 327-364Betterle C. Dal Pra C. Mantero F. Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction Endocr. Rev 2002 23 327 36410.1210/edrv.23.3.046612050123Search in Google Scholar

[35]Checchi S., Montanaro A., Ciuoli C., Brusco L., Pasqui L., Fioravanti C., Sestini F., Pacini F.: Prevalence of parietal cell antibodies in a large cohort of patients with autoimmune thyroiditis. Thyroid, 2010; 20: 1385-1389Checchi S. Montanaro A. Ciuoli C. Brusco L. Pasqui L. Fioravanti C. Sestini F. Pacini F. Prevalence of parietal cell antibodies in a large cohort of patients with autoimmune thyroiditis Thyroid 2010 20 1385 138910.1089/thy.2010.004121054212Search in Google Scholar

[36]Kahaly G.J., Frommer L.: Polyglandular autoimmune syndromes. J. Endocrinol. Invest., 2018; 41: 91-98Kahaly G.J. Frommer L. Polyglandular autoimmune syndromes J. Endocrinol. Invest 2018 41 91 9810.1007/s40618-017-0740-928819917Search in Google Scholar

[37]Nederstigt C., Uitbeijerse B.S., Janssen L.G., Corssmit E.P., de Koning E.J., Dekkers O.M.: Associated auto-immune disease in type 1 diabetes patients: A systematic review and meta-analysis. Eur. J. Endocrinol., 2019; 180: 135-144Nederstigt C. Uitbeijerse B.S. Janssen L.G. Corssmit E.P. de Koning E.J. Dekkers O.M. Associated auto-immune disease in type 1 diabetes patients: A systematic review and meta-analysis Eur. J. Endocrinol 2019 180 135 14410.1530/EJE-18-051530508413Search in Google Scholar

[38]Shimura K., Miura J., Kawamoto M., Kawaguchi Y., Yamanaka H., Uchigata Y.: Genetic differences between type 1 diabetes with and without other autoimmune diseases. Diabetes Metab. Res. Rev., 2018; 34: e3023Shimura K. Miura J. Kawamoto M. Kawaguchi Y. Yamanaka H. Uchigata Y. Genetic differences between type 1 diabetes with and without other autoimmune diseases Diabetes Metab. Res. Rev 2018 34 e302310.1002/dmrr.302329762907Search in Google Scholar

[39]Stene L.C., Rewers M.: Immunology in the clinic review series; focus on type 1 diabetes and viruses: The enterovirus link to type 1 diabetes: Critical review of human studies. Clin. Exp Immunol., 2012; 168: 12-23Stene L.C. Rewers M. Immunology in the clinic review series; focus on type 1 diabetes and viruses: The enterovirus link to type 1 diabetes: Critical review of human studies Clin. Exp Immunol 2012 168 12 2310.1111/j.1365-2249.2011.04555.x339048822385232Search in Google Scholar

[40]Wen L., Ley R.E., Volchkov P.Y., Stranges P.B., Avanesyan L., Stonebraker A.C., Hu C., Wong F.S., Szot G.L., Bluestone J.A. i wsp.: Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature, 2008; 455: 1109-1113Wen L. Ley R.E. Volchkov P.Y. Stranges P.B. Avanesyan L. Stonebraker A.C. Hu C. Wong F.S. Szot G.L. Bluestone J.A. i wsp. Innate immunity and intestinal microbiota in the development of type 1 diabetes Nature 2008 455 1109 111310.1038/nature07336257476618806780Search in Google Scholar

[41]Sepa A., Wahlberg J., Vaarala O., Frodi A., Ludvigsson J.: Psychological stress may induce diabetes-related autoimmunity in infancy. Diabetes Care, 2005; 28: 290-295Sepa A. Wahlberg J. Vaarala O. Frodi A. Ludvigsson J. Psychological stress may induce diabetes-related autoimmunity in infancy Diabetes Care 2005 28 290 29510.2337/diacare.28.2.29015677781Search in Google Scholar

[42]Bach J.F., Chatenoud L.: The hygiene hypothesis: An explanation for the increased frequency of insulin-dependent diabetes. Cold Spring Harb. Perspect. Med., 2012; 2: a007799Bach J.F. Chatenoud L. The hygiene hypothesis: An explanation for the increased frequency of insulin-dependent diabetes Cold Spring Harb. Perspect. Med 2012 2 a00779910.1101/cshperspect.a007799328159422355800Search in Google Scholar

[43]Frederiksen B., Kroehl M., Lamb M.M., Seifert J., Barriga K., Eisenbarth G.S., Rewers M., Norris J.M.: Infant exposures and development of type 1 diabetes mellitus: The diabetes autoimmunity study in the young (DAISY). JAMA Pediatr., 2013; 167: 808-815Frederiksen B. Kroehl M. Lamb M.M. Seifert J. Barriga K. Eisenbarth G.S. Rewers M. Norris J.M. Infant exposures and development of type 1 diabetes mellitus: The diabetes autoimmunity study in the young (DAISY) JAMA Pediatr 2013 167 808 81510.1001/jamapediatrics.2013.317403835723836309Search in Google Scholar

[44]Zipitis C.S., Akobeng A.K.: Vitamin D supplementation in early childhood and risk of type 1 diabetes: A systematic review and meta-analysis. Arch. Dis. Child., 2008; 93: 512-517Zipitis C.S. Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: A systematic review and meta-analysis Arch. Dis. Child 2008 93 512 51710.1136/adc.2007.12857918339654Search in Google Scholar

[45]Norris J.M., Yin X., Lamb M.M., Barriga K., Seifert J., Hoffman M., Orton H.D., Barón A.E., Clare-Salzler M., Chase H.P. i wsp.: Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA, 2007; 298: 1420-1428Norris J.M. Yin X. Lamb M.M. Barriga K. Seifert J. Hoffman M. Orton H.D. Barón A.E. Clare-Salzler M. Chase H.P. i wsp. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes JAMA 2007 298 1420 142810.1001/jama.298.12.142017895458Search in Google Scholar

[46]Hemminki K., Liu X., Försti A., Sundquist J., Sundquist K., Ji J.: Subsequent type 2 diabetes in patients with autoimmune disease. Sci. Rep., 2015; 5: 13871Hemminki K. Liu X. Försti A. Sundquist J. Sundquist K. Ji J. Subsequent type 2 diabetes in patients with autoimmune disease Sci. Rep 2015 5 1387110.1038/srep13871456336626350756Search in Google Scholar

[47]Toulis K., Tsekmekidou X., Potolidis E., Didangelos T., Gotzamani-Psarrakou A., Zebekakis P., Daniilidis M., Yovos J., Kotsa K.: Thyroid autoimmunity in the context of type 2 diabetes mellitus: Implications for vitamin D. Int. J. Endocrinol., 2015; 2015: 710363Toulis K. Tsekmekidou X. Potolidis E. Didangelos T. Gotzamani-Psarrakou A. Zebekakis P. Daniilidis M. Yovos J. Kotsa K. Thyroid autoimmunity in the context of type 2 diabetes mellitus: Implications for vitamin D Int. J. Endocrinol 2015 2015 71036310.1155/2015/710363445235526078759Search in Google Scholar

[48]Kizilgul M., Ozcelik O., Beysel S., Akinci H., Kan S., Ucan B., Apaydin M., Cakal E.: Screening for celiac disease in poorly controlled type 2 diabetes mellitus: Worth it or not? BMC Endocr. Disord., 2017; 17: 62Kizilgul M. Ozcelik O. Beysel S. Akinci H. Kan S. Ucan B. Apaydin M. Cakal E. Screening for celiac disease in poorly controlled type 2 diabetes mellitus: Worth it or not? BMC Endocr Disord 2017 17 6210.1186/s12902-017-0212-4563959728985731Search in Google Scholar

[49]Cao Y.L., Zhang F.Q., Hao F.Q.: Th1/Th2 cytokine expression in diabetic retinopathy. Genet. Mol. Res., 2016; 15: 15Cao Y.L. Zhang F.Q. Hao F.Q. Th1/Th2 cytokine expression in diabetic retinopathy Genet. Mol. Res 2016 15 1510.4238/gmr.1503731127525838Search in Google Scholar

[50]Sathyapalan T., Atkin S.L.: Is there a role for immune and antiinflammatory therapy in type 2 diabetes? Minerva Endocrinol., 2011; 36: 147-156Sathyapalan T. Atkin S.L. Is there a role for immune and antiinflammatory therapy in type 2 diabetes? Minerva Endocrinol 2011 36 147 156Search in Google Scholar

[51]Bułdak Ł., Łabuzek K., Bułdak R.J., Kozłowski M., Machnik G., Liber S., Suchy D., Duława-Bułdak A., Okopień B.: Metformin affects macrophages’ phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages. Pharmacol. Rep., 2014; 66: 418-429Bułdak Ł. Łabuzek K. Bułdak R.J. Kozłowski M. Machnik G. Liber S. Suchy D. Duława-Bułdak A. Okopień B. Metformin affects macrophages’ phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages Pharmacol. Rep 2014 66 418 42910.1016/j.pharep.2013.11.00824905518Search in Google Scholar

[52]Xu X., Lin S., Chen Y., Li X., Ma S., Fu Y., Wei C., Wang C., Xu W.: The effect of metformin on the expression of GPR109A, NF-κB and IL-1β in peripheral blood leukocytes from patients with type 2 diabetes mellitus. Ann. Clin. Lab. Sci., 2017; 47: 556-562Xu X. Lin S. Chen Y. Li X. Ma S. Fu Y. Wei C. Wang C. Xu W. The effect of metformin on the expression of GPR109A, NF-κB and IL-1β in peripheral blood leukocytes from patients with type 2 diabetes mellitus Ann. Clin. Lab. Sci 2017 47 556 562Search in Google Scholar

[53]Herder C., Dalmas E., Böni-Schnetzler M., Donath M.Y.: The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol. Metab., 2015; 26: 551-563Herder C. Dalmas E. Böni-Schnetzler M. Donath M.Y. The IL-1 pathway in type 2 diabetes and cardiovascular complications Trends Endocrinol. Metab 2015 26 551 56310.1016/j.tem.2015.08.00126412156Search in Google Scholar

[54]Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., Fonseca F., Nicolau J., Koenig W., Anker S.D. i wsp.: Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med., 2017; 377: 1119-1131Ridker P.M. Everett B.M. Thuren T. MacFadyen J.G. Chang W.H. Ballantyne C. Fonseca F. Nicolau J. Koenig W. Anker S.D. i wsp. Antiinflammatory therapy with canakinumab for atherosclerotic disease N. Engl. J. Med 2017 377 1119 113110.1056/NEJMoa170791428845751Search in Google Scholar

[55]McCaughtry T.M., Hogquist K.A.: Central tolerance: What have we learned from mice? Semin. Immunopathol., 2008; 30: 399-409McCaughtry T.M. Hogquist K.A. Central tolerance: What have we learned from mice? Semin Immunopathol 2008 30 399 40910.1007/s00281-008-0137-019015857Search in Google Scholar

[56]Gianchecchi E., Delfino D.V., Fierabracci A.: NK cells in autoimmune diseases: Linking innate and adaptive immune responses. Autoimmun. Rev., 2018; 17: 142-154Gianchecchi E. Delfino D.V. Fierabracci A. NK cells in autoimmune diseases: Linking innate and adaptive immune responses Autoimmun. Rev 2018 17 142 15410.1016/j.autrev.2017.11.01829180124Search in Google Scholar

[57]Goodnow C.C., Sprent J., Fazekas de St Groth B., Vinuesa C.G.: Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature, 2005; 435: 590-597Goodnow C.C. Sprent J. Fazekas de St Groth B. Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity Nature 2005 435 590 59710.1038/nature0372415931211Search in Google Scholar

[58]Fontenot J.D., Gavin M.A., Rudensky A.Y.: Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nat. Immunol., 2003; 4: 330-336Fontenot J.D. Gavin M.A. Rudensky A.Y. Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells Nat. Immunol 2003 4 330 33610.1038/ni90412612578Search in Google Scholar

[59]Okubo Y., Torrey H., Butterworth J., Zheng H., Faustman D.L.: Treg activation defect in type 1 diabetes: Correction with TNFR2 agonism. Clin. Transl. Immunology, 2016; 5: e56Okubo Y. Torrey H. Butterworth J. Zheng H. Faustman D.L. Treg activation defect in type 1 diabetes: Correction with TNFR2 agonism Clin. Transl. Immunology 2016 5 e5610.1038/cti.2015.43473506426900470Search in Google Scholar

[60]Wang M., Chen F., Wang J., Zeng Z., Yang Q., Shao S.: Th17 and Treg lymphocytes in obesity and Type 2 diabetic patients. Clin. Immunol., 2018; 197: 77-85Wang M. Chen F. Wang J. Zeng Z. Yang Q. Shao S. Th17 and Treg lymphocytes in obesity and Type 2 diabetic patients Clin. Immunol 2018 197 77 8510.1016/j.clim.2018.09.00530218707Search in Google Scholar

[61]El-Shabrawy R.M., Ahmed A.M., Selim F.O., Said N.M.: Association between CD4⁺, CD25⁺, FOXP3⁺ regulatory T-cells and cardiovascular complications in diabetic patients type 1. Egypt. J. Immunol., 2019; 26: 129-139El-Shabrawy R.M. Ahmed A.M. Selim F.O. Said N.M. Association between CD4⁺, CD25⁺, FOXP3⁺ regulatory T-cells and cardiovascular complications in diabetic patients type 1 Egypt. J. Immunol 2019 26 129 139Search in Google Scholar

[62]Abouzeid S., Sherif N.: Role of alteration in Treg/Th17 cells’ balance in nephropathic patients with Type 2 diabetes mellitus. Electron. Physician., 2015; 7: 1613-1618Abouzeid S. Sherif N. Role of alteration in Treg/Th17 cells’ balance in nephropathic patients with Type 2 diabetes mellitus Electron. Physician 2015 7 1613 161810.19082/1613472541526816588Search in Google Scholar

[63]Pelanda R., Piccirillo C.A.: Tolerance, immune regulation, and autoimmunity: Cells and cytokines that make a difference. Curr. Opin. Immunol., 2008; 20: 629-631Pelanda R. Piccirillo C.A. Tolerance, immune regulation, and autoimmunity: Cells and cytokines that make a difference Curr. Opin. Immunol 2008 20 629 63110.1016/j.coi.2008.10.005392741918977298Search in Google Scholar

[64]Abdel-Moneim A., Bakery H.H., Allam G.: The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed. Pharmacother., 2018; 101: 287-292Abdel-Moneim A. Bakery H.H. Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus Biomed. Pharmacother 2018 101 287 29210.1016/j.biopha.2018.02.10329499402Search in Google Scholar

[65]Qiu A.W., Liu Q.H., Wang J.L.: Blocking IL-17A alleviates diabetic retinopathy in rodents. Cell Physiol. Biochem., 2017; 41: 960-972Qiu A.W. Liu Q.H. Wang J.L. Blocking IL-17A alleviates diabetic retinopathy in rodents Cell Physiol. Biochem 2017 41 960 97210.1159/00046051428222445Search in Google Scholar

[66]Lavoz C., Rayego-Mateos S., Orejudo M., Opazo-Ríos L., Marchant V., Marquez-Exposito L., Tejera-Muñoz A., Navarro-González J.F., Droguett A., Ortiz A. i wsp.: Could IL-17A be a novel therapeutic target in diabetic nephropathy? J. Clin. Med., 2020; 9: 272Lavoz C. Rayego-Mateos S. Orejudo M. Opazo-Ríos L. Marchant V. Marquez-Exposito L. Tejera-Muñoz A. Navarro-González J.F. Droguett A. Ortiz A. i wsp. Could IL-17A be a novel therapeutic target in diabetic nephropathy? J Clin. Med 2020 9 27210.3390/jcm9010272701937331963845Search in Google Scholar

[67]Cortvrindt C., Speeckaert R., Moerman A., Delanghe J.R., Speeckaert M.M.: The role of interleukin-17A in the pathogenesis of kidney diseases. Pathology, 2017; 49: 247-258Cortvrindt C. Speeckaert R. Moerman A. Delanghe J.R. Speeckaert M.M. The role of interleukin-17A in the pathogenesis of kidney diseases Pathology 2017 49 247 25810.1016/j.pathol.2017.01.00328291548Search in Google Scholar

[68]Gauci M.L., Boudou P., Baroudjian B., Vidal-Trecan T., Da Meda L., Madelaine-Chambrin I., Basset-Seguin N., Bagot M., Pages C., Mourah S. i wsp.: Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: A retrospective study. Cancer Immunol. Immunother., 2018; 67: 1197-1208Gauci M.L. Boudou P. Baroudjian B. Vidal-Trecan T. Da Meda L. Madelaine-Chambrin I. Basset-Seguin N. Bagot M. Pages C. Mourah S. i wsp. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: A retrospective study Cancer Immunol. Immunother 2018 67 1197 120810.1007/s00262-018-2178-029808365Search in Google Scholar

[69]Parenti A., Pala L., Paccosi S., Rotella C.M.: Potential role for dendritic cells in endothelial dysfunction, diabetes and cardiovascular disease. Curr. Pharm. Des., 2017; 23: 1435-1444Parenti A. Pala L. Paccosi S. Rotella C.M. Potential role for dendritic cells in endothelial dysfunction, diabetes and cardiovascular disease Curr. Pharm. Des 2017 23 1435 144410.2174/138161282366617012412582628120714Search in Google Scholar

[70]Mráz M., Cinkajzlová A., Kloučková J., Lacinová Z., Kratochvílová H., Lipš M., Pořízka M., Kopecký P., Lindner J., Kotulák T. i wsp.: Dendritic cells in subcutaneous and epicardial adipose tissue of subjects with type 2 diabetes, obesity, and coronary artery disease. Mediators Inflamm., 2019; 2019: 5481725Mráz M. Cinkajzlová A. Kloučková J. Lacinová Z. Kratochvílová H. Lipš M. Pořízka M. Kopecký P. Lindner J. Kotulák T. i wsp. Dendritic cells in subcutaneous and epicardial adipose tissue of subjects with type 2 diabetes, obesity, and coronary artery disease Mediators Inflamm 2019 2019 548172510.1155/2019/5481725653227431210749Search in Google Scholar

[71]Marca V., Gianchecchi E., Fierabracci A.: Type 1 diabetes and its multi-factorial pathogenesis: The putative role of NK cells. Int. J. Mol. Sci., 2018; 19: 794Marca V. Gianchecchi E. Fierabracci A. Type 1 diabetes and its multi-factorial pathogenesis: The putative role of NK cells Int. J. Mol. Sci 2018 19 79410.3390/ijms19030794587765529534427Search in Google Scholar

[72]Chiba H., Fukui A., Fuchinoue K., Funamizu A., Tanaka K., Mizunuma H.: Expression of natural cytotoxicity receptors on and intracellular cytokine production by NK cells in women with gestational diabetes mellitus. Am. J. Reprod. Immunol., 2016; 75: 529538Chiba H. Fukui A. Fuchinoue K. Funamizu A. Tanaka K. Mizunuma H. Expression of natural cytotoxicity receptors on and intracellular cytokine production by NK cells in women with gestational diabetes mellitus Am. J. Reprod. Immunol 2016 75 52953810.1111/aji.1249126813019Search in Google Scholar

[73]Lobo T.F., Borges C.M., Mattar R., Gomes C.P., de Angelo A.G., Pendeloski K.P., Daher S.: Impaired Treg and NK cells profile in overweight women with gestational diabetes mellitus. Am. J. Reprod. Immunol., 2018; 79: e12810Lobo T.F. Borges C.M. Mattar R. Gomes C.P. de Angelo A.G. Pendeloski K.P. Daher S. Impaired Treg and NK cells profile in overweight women with gestational diabetes mellitus Am. J. Reprod. Immunol 2018 79 e1281010.1111/aji.1281029315988Search in Google Scholar

[74]Tylutka A., Zembroń-Łacny A.: Starzenie się układu immunologicznego i jego konsekwencje dla zdrowia. Postępy Hig. Med. Dośw., 2020; 74: 259-270Tylutka A. Zembroń-Łacny A. Starzenie się układu immunologicznego i jego konsekwencje dla zdrowia Postępy Hig. Med. Dośw 2020 74 259 27010.5604/01.3001.0014.3054Search in Google Scholar

[75]Wańkowicz-Kalińska A.: Zjawiska autoimmunizacyjne. W: Immunologia, red.: J. Gołąb, M. Jakóbisiak, W. Lasek, T. Stokłosa. PWN, Warszawa 2012, 360-362Wańkowicz-Kalińska A. Zjawiska autoimmunizacyjne. W: Immunologia, red.: J. Gołąb, M. Jakóbisiak, W. Lasek, T. Stokłosa PWN, Warszawa 2012 360 362Search in Google Scholar

[76]Nikolov A., Tzekova M., Blazhev A.: Relationship between lipid indices, type IV collagen turnover and the development of microvascular complications in diabetic patients with arterial hypertension. Folia Med., 2019; 61: 231-239Nikolov A. Tzekova M. Blazhev A. Relationship between lipid indices, type IV collagen turnover and the development of microvascular complications in diabetic patients with arterial hypertension Folia Med 2019 61 231 23910.2478/folmed-2018-007231301656Search in Google Scholar

[77]Attawia M.A., Nayak R.C.: Circulating antipericyte autoantibodies in diabetic retinopathy. Retina, 1999; 19: 390-400Attawia M.A. Nayak R.C. Circulating antipericyte autoantibodies in diabetic retinopathy Retina 1999 19 390 40010.1097/00006982-199909000-0000410546933Search in Google Scholar

[78]Nayak R.C., Agardh C.D., Kwok M.G., Stjernquist H., Farthing-Nayak P.J., Agardh E.: Circulating anti-pericyte autoantibodies are present in type 2 diabetic patients and are associated with non-proliferative retinopathy. Diabetologia, 2003; 46: 511-513Nayak R.C. Agardh C.D. Kwok M.G. Stjernquist H. Farthing-Nayak P.J. Agardh E. Circulating anti-pericyte autoantibodies are present in type 2 diabetic patients and are associated with non-proliferative retinopathy Diabetologia 2003 46 511 51310.1007/s00125-003-1057-012739023Search in Google Scholar

[79]Zhang L., Li Y., Payne J., Srivastava S., Fan X., Fung J., Li X., Kern T.S., Lin F.: Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients. Sci. Rep., 2016; 6: 20341Zhang L. Li Y. Payne J. Srivastava S. Fan X. Fung J. Li X. Kern T.S. Lin F. Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients Sci. Rep 2016 6 2034110.1038/srep20341473825826839120Search in Google Scholar

[80]Fredrikson G.N., Anand D.V., Hopkins D., Corder R., Alm R., Bengtsson E., Shah P.K., Lahiri A., Nilsson J.: Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia, 2009; 52: 1426-1433Fredrikson G.N. Anand D.V. Hopkins D. Corder R. Alm R. Bengtsson E. Shah P.K. Lahiri A. Nilsson J. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes Diabetologia 2009 52 1426 143310.1007/s00125-009-1377-9268861119448981Search in Google Scholar

[81]Vavuli S., Salonurmi T., Loukovaara S., Nissinen A.E., Savolainen M.J., Liinamaa M.J.: Elevated levels of plasma IgA autoantibodies against oxidized LDL found in proliferative diabetic retinopathy but not in nonproliferative retinopathy. J. Diabetes Res., 2016; 2016: 2614153Vavuli S. Salonurmi T. Loukovaara S. Nissinen A.E. Savolainen M.J. Liinamaa M.J. Elevated levels of plasma IgA autoantibodies against oxidized LDL found in proliferative diabetic retinopathy but not in nonproliferative retinopathy J. Diabetes Res 2016 2016 261415310.1155/2016/2614153520645728090539Search in Google Scholar

[82]Sinha S., Saxena S., Das S., Prasad S., Bhasker S.K., Mahdi A.A., Kruzliak P.: Antimyeloperoxidase antibody is a biomarker for progression of diabetic retinopathy. J. Diabetes Complications, 2016; 30: 700-704Sinha S. Saxena S. Das S. Prasad S. Bhasker S.K. Mahdi A.A. Kruzliak P. Antimyeloperoxidase antibody is a biomarker for progression of diabetic retinopathy J. Diabetes Complications 2016 30 700 70410.1016/j.jdiacomp.2016.01.01026948921Search in Google Scholar

[83]Yoshitake S., Murakami T., Suzuma K., Yoshitake T., Uji A., Morooka S., Dodo Y., Fujimoto M., Shan Y., Fort P.E. i wsp.: Antifumarase antibody promotes the dropout of photoreceptor inner and outer segments in diabetic macular oedema. Diabetologia, 2019; 62: 504-516Yoshitake S. Murakami T. Suzuma K. Yoshitake T. Uji A. Morooka S. Dodo Y. Fujimoto M. Shan Y. Fort P.E. i wsp. Antifumarase antibody promotes the dropout of photoreceptor inner and outer segments in diabetic macular oedema Diabetologia 2019 62 504 51610.1007/s00125-018-4773-1644133630488085Search in Google Scholar

[84]Türk A., Mollamehmetoğlu S., Alver A., Menteşe A., Nuhoğlu I., Erem C., Imamoğlu H.I.: The relationship between serum carbonic anhydrase I-II autoantibody levels and diabetic retinopathy in type 1 diabetes patients. Turk. J. Ophthalmol., 2017; 47: 85-88Türk A. Mollamehmetoğlu S. Alver A. Menteşe A. Nuhoğlu I. Erem C. Imamoğlu H.I. The relationship between serum carbonic anhydrase I-II autoantibody levels and diabetic retinopathy in type 1 diabetes patients Turk. J. Ophthalmol 2017 47 85 8810.4274/tjo.99233538412528405482Search in Google Scholar

[85]Nakaizumi A., Fukumoto M., Kida T., Suzuki H., Morishita S., Satou T., Oku H., Ikeda T., Nakamura K.: Measurement of serum and vitreous concentrations of anti-type II collagen antibody in diabetic retinopathy. Clin. Ophthalmol., 2015; 9: 543-547Nakaizumi A. Fukumoto M. Kida T. Suzuki H. Morishita S. Satou T. Oku H. Ikeda T. Nakamura K. Measurement of serum and vitreous concentrations of anti-type II collagen antibody in diabetic retinopathy Clin. Ophthalmol 2015 9 543 54710.2147/OPTH.S75422437629925848204Search in Google Scholar

[86]Lopes-Virella M.F., Hunt K.J., Baker N.L., Virella G., VADT Group of Investigators: High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDALDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J. Diabetes Complications, 2016; 30: 693-699Lopes-Virella M.F. Hunt K.J. Baker N.L. Virella G. VADT Group of Investigators High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDALDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes J. Diabetes Complications 2016 30 693 69910.1016/j.jdiacomp.2016.01.01226861948Search in Google Scholar

[87]Virella G., Carter R.E., Saad A., Crosswell E.G., Game B.A., DCCT/EDIC Study Group, Lopes-Virella M.F.: Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin. Immunol., 2008; 127: 394-400Virella G. Carter R.E. Saad A. Crosswell E.G. Game B.A. DCCT/EDIC Study Group Lopes-Virella M.F. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy Clin. Immunol 2008 127 394 40010.1016/j.clim.2008.02.005260155818533284Search in Google Scholar

[88]Zimering M.B., Zhang J.H., Guarino P.D., Emanuele N., McCullough P.A., Fried L.F., Investigators for the VA NEPHRON-D: Endothelial cell autoantibodies in predicting declining renal function, end-stage renal disease, or death in adult type 2 diabetic nephropathy. Front. Endocrinol., 2014; 5: 128Zimering M.B. Zhang J.H. Guarino P.D. Emanuele N. McCullough P.A. Fried L.F. Investigators for the VA NEPHRON-D Endothelial cell autoantibodies in predicting declining renal function, end-stage renal disease, or death in adult type 2 diabetic nephropathy Front. Endocrinol 2014 5 12810.3389/fendo.2014.00128Search in Google Scholar

[89]Ge S., Xie J., Zheng L., Yang L., Zhu H., Cheng X., Shen F.: Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy. Diabetes Res. Clin. Pract., 2016; 115: 68-75Ge S. Xie J. Zheng L. Yang L. Zhu H. Cheng X. Shen F. Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy Diabetes Res. Clin. Pract 2016 115 68 7510.1016/j.diabres.2016.02.00527242125Search in Google Scholar

[90]Menichella D.M., Jayaraj N.D., Wilson H.M., Ren D., Flood K., Wang X.Q., Shum A., Miller R.J., Paller A.S.: Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice. Mol. Pain, 2016; 12: 1744806916666284Menichella D.M. Jayaraj N.D. Wilson H.M. Ren D. Flood K. Wang X.Q. Shum A. Miller R.J. Paller A.S. Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice Mol. Pain 2016 12 174480691666628410.1177/1744806916666284501139327590073Search in Google Scholar

[91]Ejskjaer N., Arif S., Dodds W., Zanone M.M., Vergani D., Watkins P.J., Peakman M.: Prevalence of autoantibodies to autonomic nervous tissue structures in type 1 diabetes mellitus. Diabet. Med.; 1999; 16: 544-549Ejskjaer N. Arif S. Dodds W. Zanone M.M. Vergani D. Watkins P.J. Peakman M. Prevalence of autoantibodies to autonomic nervous tissue structures in type 1 diabetes mellitus Diabet. Med.; 1999 16 544 54910.1046/j.1464-5491.1999.00092.x10445828Search in Google Scholar

[92]Gottumukkala R.V., Lv H., Cornivelli L., Wagers A.J., Kwong R.Y., Bronson R., Stewart G.C., Schulze P.C., Chutkow W., Wolpert H.A. i wsp.: Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci. Transl. Med., 2012; 4: 138ra80Gottumukkala R.V. Lv H. Cornivelli L. Wagers A.J. Kwong R.Y. Bronson R. Stewart G.C. Schulze P.C. Chutkow W. Wolpert H.A. i wsp. Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes Sci. Transl. Med 2012 4 138ra8010.1126/scitranslmed.3003551430325922700956Search in Google Scholar

[93]Hoffman W.H., Sharma M., Cihakova D., Talor M.V., Rose N.R., Mohanakumar T., Passmore G.G.: Cardiac antibody production to self-antigens in children and adolescents during and following the correction of severe diabetic ketoacidosis. Autoimmunity, 2016; 49: 188-196Hoffman W.H. Sharma M. Cihakova D. Talor M.V. Rose N.R. Mohanakumar T. Passmore G.G. Cardiac antibody production to self-antigens in children and adolescents during and following the correction of severe diabetic ketoacidosis Autoimmunity 2016 49 188 19610.3109/08916934.2015.113450926911924Search in Google Scholar

[94]Roth B., Berntorp K., Ohlsson B.: The expression of serum antibodies against gonadotropin-releasing hormone (GnRH1), progonadoliberin-2, luteinizing hormone (LH), and related receptors in patients with gastrointestinal dysfunction or diabetes mellitus. Drug Target Insights, 2014; 8: 45-50Roth B. Berntorp K. Ohlsson B. The expression of serum antibodies against gonadotropin-releasing hormone (GnRH1), progonadoliberin-2, luteinizing hormone (LH), and related receptors in patients with gastrointestinal dysfunction or diabetes mellitus Drug Target Insights 2014 8 45 5010.4137/DTI.S19352422761825452692Search in Google Scholar

[95]Rizzo P., Pitocco D., Zaccardi F., Di Stasio E., Strollo R., Rizzi A., Scavone G., Costantini F., Galli M., Tinelli G. i wsp.: Autoantibodies to post-translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus. Diabetes Metab. Res. Rev., 2017; 33: e2839Rizzo P. Pitocco D. Zaccardi F. Di Stasio E. Strollo R. Rizzi A. Scavone G. Costantini F. Galli M. Tinelli G. i wsp. Autoantibodies to post-translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus Diabetes Metab. Res. Rev 2017 33 e283910.1002/dmrr.283927454862Search in Google Scholar

[96]Xiao X., Ma B., Dong B., Zhao P., Tai N., Chen L., Wong F.S., Wen L.: Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice. J. Autoimmun., 2009; 32: 85-93Xiao X. Ma B. Dong B. Zhao P. Tai N. Chen L. Wong F.S. Wen L. Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice J. Autoimmun 2009 32 85 9310.1016/j.jaut.2008.12.00319200691Search in Google Scholar

[97]Nicoloff G., Blazhev A., Petrova C., Christova P.: Circulating immune complexes among diabetic children. Clin. Dev. Immunol., 2004; 11: 61-66Nicoloff G. Blazhev A. Petrova C. Christova P. Circulating immune complexes among diabetic children Clin. Dev. Immunol 2004 11 61 6610.1080/10446670410001670517227540715154614Search in Google Scholar

[98]Li T., Yu Z., Qu Z., Zhang N., Crew R., Jiang Y.: Decreased number of CD19⁺CD24^hiCD^38hi regulatory B cells in diabetic nephropathy. Mol. Immunol., 2019; 112: 233-239Li T. Yu Z. Qu Z. Zhang N. Crew R. Jiang Y. Decreased number of CD19⁺CD24^hiCD^38hi regulatory B cells in diabetic nephropathy Mol. Immunol 2019 112 233 23910.1016/j.molimm.2019.05.01431181422Search in Google Scholar

[99]Zhang N., Tai J., Qu Z., Zhang Z., Zhao S., He J., Zhang S., Jiang Y.: Increased CD4⁺CXCR5⁺ T follicular helper cells in diabetic nephropathy. Autoimmunity, 2016; 49: 405-413Zhang N. Tai J. Qu Z. Zhang Z. Zhao S. He J. Zhang S. Jiang Y. Increased CD4⁺CXCR5⁺ T follicular helper cells in diabetic nephropathy Autoimmunity 2016 49 405 41310.1080/08916934.2016.119667727477820Search in Google Scholar

[100]Cameron N.E., Eaton S.E., Cotter M.A., Tesfaye S.: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 2001; 44: 1973-1988Cameron N.E. Eaton S.E. Cotter M.A. Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy Diabetologia 2001 44 1973 198810.1007/s00125010000111719828Search in Google Scholar

[101]Elzinga S., Murdock B.J., Guo K., Hayes J.M., Tabbey M.A., Hur J., Feldman E.L.: Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease? Exp. Neurol., 2019; 320: 112967Elzinga S. Murdock B.J. Guo K. Hayes J.M. Tabbey M.A. Hur J. Feldman E.L. Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease? Exp Neurol 2019 320 11296710.1016/j.expneurol.2019.112967Search in Google Scholar

[102]Janahi N.M., Santos D., Blyth C., Bakhiet M., Ellis M.: Diabetic peripheral neuropathy, is it an autoimmune disease? Immunol. Lett., 2015;168: 73-79Janahi N.M. Santos D. Blyth C. Bakhiet M. Ellis M. Diabetic peripheral neuropathy, is it an autoimmune disease? Immunol Lett 2015168 73 7910.1016/j.imlet.2015.09.009Search in Google Scholar

[103]Zanone M.M., Raviolo A., Coppo E., Trento M., Trevisan M., Cavallo F., Favaro E., Passera P., Porta M., Camussi G.: Association of autoimmunity to autonomic nervous structures with nerve function in patients with type 1 diabetes: A 16-year prospective study. Diabetes Care, 2014; 37: 1108-1115Zanone M.M. Raviolo A. Coppo E. Trento M. Trevisan M. Cavallo F. Favaro E. Passera P. Porta M. Camussi G. Association of autoimmunity to autonomic nervous structures with nerve function in patients with type 1 diabetes: A 16-year prospective study Diabetes Care 2014 37 1108 111510.2337/dc13-227424550215Search in Google Scholar

[104]Schnell O., Schwarz A., Muhr-Becker D., Standl E.: Autoantibodies against autonomic nervous tissues in type 2 diabetes mellitus: No association with cardiac autonomic dysfunction. Exp. Clin. Endocrinol. Diabetes, 2000; 108: 181-186Schnell O. Schwarz A. Muhr-Becker D. Standl E. Autoantibodies against autonomic nervous tissues in type 2 diabetes mellitus: No association with cardiac autonomic dysfunction Exp. Clin. Endocrinol. Diabetes 2000 108 181 18610.1055/s-2000-774110926313Search in Google Scholar

[105]Łukawska-Tatarczuk M., Mrozikiewicz-Rakowska B., Franek E., Czupryniak L.: Podłoże molekularne niewydolności serca w cukrzycy – nowe możliwości terapeutyczne. Postępy Hig. Med. Dośw., 2020; 74: 452-463Łukawska-Tatarczuk M. Mrozikiewicz-Rakowska B. Franek E. Czupryniak L. Podłoże molekularne niewydolności serca w cukrzycy – nowe możliwości terapeutyczne Postępy Hig. Med. Dośw 2020 74 452 46310.5604/01.3001.0014.4856Search in Google Scholar

[106]Lv H., Havari E., Pinto S., Gottumukkala R.V., Cornivelli L., Raddassi K., Matsui T., Rosenzweig A., Bronson R.T., Smith R. i wsp.: Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans. J. Clin. Invest., 2011; 121: 1561-1573Lv H. Havari E. Pinto S. Gottumukkala R.V. Cornivelli L. Raddassi K. Matsui T. Rosenzweig A. Bronson R.T. Smith R. i wsp. Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans J. Clin. Invest 2011 121 1561 157310.1172/JCI44583306977621436590Search in Google Scholar

[107]Sousa G.R., Pober D., Galderisi A., Lv H., Yu L., Pereira A.C., Doria A., Kosiborod M., Lipes M.A.: Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus. Circulation, 2019; 139: 730-743Sousa G.R. Pober D. Galderisi A. Lv H. Yu L. Pereira A.C. Doria A. Kosiborod M. Lipes M.A. Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus Circulation 2019 139 730 74310.1161/CIRCULATIONAHA.118.036068636169330586738Search in Google Scholar

[108]Tomaszewska A., Mrozikiewicz-Rakowska B., Czupryniak L.: Diabetic enteropathy – still undefeated? Clin. Diabetology, 2017; 6: 105-110Tomaszewska A. Mrozikiewicz-Rakowska B. Czupryniak L. Diabetic enteropathy – still undefeated? Clin Diabetology 2017 6 105 11010.5603/DK.2017.0017Search in Google Scholar

[109]D’Addio F., La Rosa S., Maestroni A., Jung P., Orsenigo E., Ben Nasr M., Tezza S., Bassi R., Finzi G., Marando A. i wsp.: Circulating IGF-I and IGFBP3 levels control human colonic stem cell function and are disrupted in diabetic enteropathy. Cell Stem Cell, 2015; 17: 486-498D’Addio F. La Rosa S. Maestroni A. Jung P. Orsenigo E. Ben Nasr M. Tezza S. Bassi R. Finzi G. Marando A. i wsp. Circulating IGF-I and IGFBP3 levels control human colonic stem cell function and are disrupted in diabetic enteropathy Cell Stem Cell 2015 17 486 49810.1016/j.stem.2015.07.010482627926431183Search in Google Scholar

[110]Bereket A., Lang C.H., Wilson T.A.: Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm. Metab. Res., 1999; 31: 172-181Bereket A. Lang C.H. Wilson T.A. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus Horm. Metab. Res 1999 31 172 18110.1055/s-2007-97871610226799Search in Google Scholar